World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
37950
World Ranking
12962
National Ranking
6627

Chandra P. Belani publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Chandra P. Belani sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 586 publications — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Chandra P. Belani D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Chandra P. Belani sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Chandra P. Belani is affiliated with the Penn State Cancer Institute in the United States. Their research primarily focuses on the fields of Medicine, with particular attention to Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, and Spectroscopy.

The scientist's main research themes encompass several specialized topics, including:

  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • Lung Cancer Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Lung Cancer Research Studies
  • Advanced Proteomics Techniques and Applications
  • Mass Spectrometry Techniques and Applications

Chandra P. Belani's recent publications include significant contributions to the understanding and management of lung cancer. Notable works are:

  • "Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer," 2021, Journal of Thoracic Oncology
  • "The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer," 2020, Journal of Thoracic Oncology
  • "Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic," 2020, Journal of Thoracic Oncology
  • "International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy," 2023, Journal of Thoracic Oncology
  • "Optimizing data-independent acquisition (DIA) spectral library workflows for plasma proteomics studies," 2022, PROTEOMICS

Frequent collaborators include:

  • Suresh S. Ramalingam
  • Giorgio V. Scagliotti
  • Murry W. Wynes
  • Shawn J. Rice
  • Madhusmita Behera

The scientist frequently publishes in the following venues:

  • Journal of Thoracic Oncology
  • JTO Clinical and Research Reports
  • UNC Libraries
  • PROTEOMICS
  • The Oncologist

Best Publications

  • Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

    Joan H. Schiller;David Harrington;Chandra P. Belani;Corey Langer

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Thomas J. Lynch

  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

    Tudor Ciuleanu;Thomas Brodowicz;Christoph Zielinski;Joo Hang Kim

  • Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study Group

    Frank Fossella;Jose R. Pereira;Joachim von Pawel;Anna Pluzanska

  • Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database

    Taofeek K. Owonikoko;Camille C. Ragin;Chandra P. Belani;Ana B. Oton

  • Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Chemotherapy or Erlotinib Compared With Chemotherapy Alone for Treatment of Recurrent or Refractory Non–Small-Cell Lung Cancer

    Roy S. Herbst;Vincent J. O'Neill;Louis Fehrenbacher;Chandra P. Belani

  • Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol

    Chandra P. Belani;Hak Choy;Phil Bonomi;Charles Scott

  • Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

    Suresh S. Ramalingam;Suzanne E. Dahlberg;Corey J. Langer;Robert Gray

  • Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions

    Suresh Ramalingam;Chandra Belani

  • Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

    Christian Rolfo;Philip Mack;Giorgio V. Scagliotti;Charu Aggarwal

  • Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

    Mark A. Socinski;Silvia Novello;Julie R. Brahmer;Rafael Rosell

  • Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma

    Christopher J. Sweeney;Junming Zhu;Alan B. Sandler;Joan Schiller

  • Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer

    John V. Heymach;Bruce E. Johnson;Diane Prager;Edit Csada

  • Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.

    Giorgio V. Scagliotti;Thomas Brodowicz;Frances A. Shepherd;Christoph Zielinski

  • A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

    Ramesh K. Ramanathan;Chandra P. Belani;Deepti A. Singh;Michael Tanaka

  • Multicenter, Randomized Trial for Stage IIIB or IV Non–Small-Cell Lung Cancer Using Weekly Paclitaxel and Carboplatin Followed by Maintenance Weekly Paclitaxel or Observation

    Chandra P. Belani;John Barstis;Michael C. Perry;Renato V. La Rocca

  • Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale

    R.N. Patricia J. Hollen Ph.D.;Richard J. Gralla;Mark G. Kris;Christopher Cox

  • Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

    Suresh S. Ramalingam;Michael L. Maitland;Paul Frankel;Athanassios E. Argiris

  • Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

    Audrey Mauguen;Cécile Le Péchoux;Michele I. Saunders;Steven E. Schild

  • Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer

    Mark G. Kris;Ronald B. Natale;Roy S. Herbst;Diane Prager

Frequent Co-Authors

Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
Taofeek K. Owonikoko
Taofeek K. Owonikoko Emory University
Fadlo R. Khuri
Fadlo R. Khuri American University of Beirut
James D. Luketich
James D. Luketich University of Pittsburgh
David R. Gandara
David R. Gandara University of California, Davis
Xin Liu
Xin Liu Chinese Academy of Sciences
Mark A. Socinski
Mark A. Socinski University of North Carolina at Chapel Hill
David H. Johnson
David H. Johnson The University of Texas Southwestern Medical Center
John C. Flickinger
John C. Flickinger University of Pittsburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re passionate about a career in medicine but want to explore alternative or supportive pathways, the healthcare field offers a wide variety of online degree options. Many professionals choose flexible online programs to advance their qualifications at their own pace.

Students interested in the highest levels of nursing may consider online dnp programs without clinicals, which can reduce time spent on in-person training and streamline the learning process for experienced nurses. Those who wish to enter the nursing profession quickly might explore fast track lpn programs—these are designed to help you become a Licensed Practical Nurse in less time.

Mental health is an in-demand specialty. The fastest psych np program options allow working nurses to efficiently specialize in psychiatric mental health, opening the door to new career opportunities.

Not every path leads to clinical roles. For those who prefer the business side of healthcare, an online healthcare administration programs can prepare you for leadership and management positions in hospitals, clinics, or other healthcare settings.

Best Scientists Citing Chandra P. Belani

Trending Scientists

Recently Published Articles